Loading
A phase 1/2 trial of YL201 for Injection in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., active and no longer recruiting.
A Study YL201 in Patients With Selected Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06057922 by MediLink Therapeutics (Suzhou) Co., Ltd., with 990 participants enrolled, started 2023-09-22 and due to reach its primary completion in 2026-10. Interventions recorded: YL201 for Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares YL201, MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares YL201 and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/